Dothistromin is a natural product mycotoxin produced by the fungal pathogen Dothistroma septosporum, which causes dothistroma needle blight in pine trees. It is a highly potent phytotoxin, exhibiting significant effects on plant growth and development. Dothistromin has been shown to inhibit photosynthesis, induce oxidative stress, and disrupt cell wall biosynthesis in plants. Research on dothistromin focuses on understanding its mechanisms of action, its role in disease development, and potential strategies for disease management. The compound's impact on plant health, particularly in forestry, makes it an important subject of study.'
dothistromin: metabolite of peanut pathogen Cercospora arachidicola; RN given refers to (2R-(2alpha,3abeta,12abeta))-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 108014 |
| CHEBI ID | 4704 |
| MeSH ID | M0126047 |
| Synonym |
|---|
| anthra(2,3-b)furo(3,2-d)furan-5,10-dione, 2,3,3a,12a-tetrahydro-2,3a,4,6,9-pentahydroxy-, stereoisomer |
| anthra(2,3-b)furo(3,2-d)furan-5,10-dione, 2,3,3a,12a-tetrahydro-2,3a,4,6,9-pentahydroxy-, (2r,3ar,12as)- |
| unii-27usw980dl |
| 27usw980dl , |
| 31456-72-1 |
| dothistromin |
| anthra(2,3-b)furo(3,2-d)furan-5,10-dione, 2,3,3a,12a-tetrahydro-2,3a,4,6,9-pentahydroxy-, (2r-(2.alpha.,3a.beta.,12a.beta.))- |
| CHEBI:4704 |
| Q27106442 |
| (4r,6r,8s)-2,4,6,15,18-pentahydroxy-7,9-dioxapentacyclo[10.8.0.03,10.04,8.014,19]icosa-1,3(10),11,14,16,18-hexaene-13,20-dione |
| DTXSID50953471 |
| 2,3a,4,6,9-pentahydroxy-2,3,3a,12a-tetrahydroanthra[2,3-b]furo[3,2-d]furan-5,10-dione |
Dothistromin is a mycotoxin that is remarkably similar in structure to versicolorin B, a precursor of both aflatoxin and sterigmatocystin. It is a broad-range toxin and possibly involved in red-band needle blight disease.
| Class | Description |
|---|---|
| anthraquinone | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (10.53) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 6 (31.58) | 29.6817 |
| 2010's | 10 (52.63) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.21) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (10.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (90.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||